Axsome Therapeutics AXSM Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's retained earnings?
- Axsome Therapeutics (AXSM) reported retained earnings of -$1.37B in Q1 2026.
- How has Axsome Therapeutics's retained earnings changed year-over-year?
- Axsome Therapeutics's retained earnings decreased by 15.9% year-over-year, from -$1.18B to -$1.37B.
- What is the long-term trend for Axsome Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Axsome Therapeutics's retained earnings has grown at a 36.2% compound annual growth rate (CAGR), from -$278.8M to -$1.31B.
- What does retained earnings mean?
- The cumulative profit or loss the company has generated since it started.
- How do you interpret retained earnings?
- A move toward positive values indicates the company is becoming self-sustaining and profitable.
- How does retained earnings compare across companies?
- Often negative for clinical-stage firms; positive for mature, commercial-stage pharmaceutical companies.